Articles tagged "P-glycoprotein"

2022 American Transplant Congress
Differences of Fk-Binding Protein 12 and P-Glycoprotein Explain the Differences in the Intracellular Tacrolimus Concentration of T Lymphocytes and Monocytes
S. Udomkarnjananun, C. Baan, B. de Winter, D. Hesselink
Erasmus MC, Rotterdam, Netherlands
*Purpose: Little is known about the pharmacokinetics of intracellular tacrolimus, particularly in T lymphocytes and monocytes. We demonstrated a significantly lower intracellular tacrolimus concentration in…
2016 American Transplant Congress
P-Glycoprotein Function: Association with Race, Gender and Tacrolimus Pharmacokinetics.
K. Tornatore,^1,4 H. Minderman,² K. Attwood,³ K. O'Loughlin,² R. Venuto.⁴
¹Translational Pharmacology Research, School of Pharmacy, Buffalo; ²Flow Cytometry Laboratory, Roswell Park Cancer Institute, Buffalo; ³Biostatistics, School of Public Health, Buffalo; ⁴Medicine, School of Medicine;UB, Buffalo.
Background: Long term allograft survival remains poorer in African American(AA) renal transplant recipients(RTR) compared to Caucasians(C) and may be due to racial differences in calcineurin…
2015 American Transplant Congress
Influence of Race on P-Glycoprotein Function in Peripheral Blood Mononuclear Cells
K. Tornatore,¹ H. Minderman,² K. O'Loughlin,² K. Attwood,³ D. Brazeau,⁴ R. Venuto.⁵
¹NYS Center of Excellence in Bioinformatics & Life Science, School of Pharmacy, Buffalo; ²Flow Cytometry Laboratories, Roswell Park Cancer Institute, Buffalo; ³Biostatistics, School of Public Health, Buffalo; ⁴University of New England; School of Pharmacy, Portland, ME; ⁵Medicine, School of Medicine; University at Buffalo, Buffalo, NY.
Purpose: African Americans (AA) renal transplant recipients (RTR) have poorer long term allograft survival compared to Caucasians(C) which may be attributed to racial differences in…
2015 American Transplant Congress
Pharmacogenetic Variation in Renal Calcineurin Inhibitor (CNI) Metabolism and the Response of Allograft-Derived Proximal Tubule Cells
N. Knops,^1,2 L. van den Heuvel,² R. Masereeuw,³ H. de Loor,⁴ E. Levtchenko,^1,2 D. Kuypers.^5,4
¹Pediatric Nephrology and Solid Organ Transplantation, University Hospitals Leuven, Leuven, Belgium; ²Laboratory for Pediatrics, Dept. Development & Regeneration, KU Leuven, Leuven, Belgium; ³Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, Netherlands; ⁴Laboratory of Nephrology, University Hospitals Leuven, Leuven, Belgium; ⁵Nephrology and Solid Organ Transplantation, University Hospital Leuven, Leuven, Belgium.
Background: Multiple studies have demonstrated the importance of genetic variation in CYP3A5 and ABCB1 for calcineurin inhibitor (CNI) disposition and CNI-related nephrotoxicity. Renal CNI metabolism…
2015 American Transplant Congress
ABCB1 Haplotypes, Sex, Calcineurin Inhibitors and Lipid Profiles Post-Renal Transplant
C. Meaney,^1,2 R. Venuto,³ D. Brazeau,⁴ J. Consiglio,⁵ L. Cooper,¹ G. Wilding,⁵ K. Tornatore.^1,2,3
¹NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, NY; ²School of Pharmacy, Buffalo, NY; ³Medicine, School of Medicine, Buffalo, NY; ⁴University of New England College of Pharmacy, Portland, ME; ⁵Biostatistics, School of Public Health, University at Buffalo, Buffalo, NY.
Purpose: Hyperlipidemia is common in renal transplant recipients (RTR) during calcineurin inhibitor (CNI) immunosuppression. P-glycoprotein (P-gp) is an efflux transporter encoded by ABCB1 that modulates…
2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
T. Elnahhas,^1,2 T. Lee,² M. Moreton,² D. McKeown,² J. Popoola,³ R. Ramkhelawon,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom.
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…